Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H C Lane

Showing results (191-200 of 209) with videos related to

Pageof 21
Sort By:
The Journal of Infectious Diseases|April 1, 1996
Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trialJ A Kovacs, C Bechtel, R T Davey, et al.
The Journal of Infectious Diseases|September 9, 2000
Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expressionJ A Kovacs, H Imamichi, S Vogel, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1997
Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infectionM A Polis, S C Piscitelli, S Vogel, et al.
The Journal of Infectious Diseases|May 24, 2000
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3M H Losso, W H Belloso, S Emery, et al.
Journal of Virology|July 11, 1996
Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1R Shibata, C Siemon, M W Cho, et al.
The Journal of Antimicrobial Chemotherapy|March 15, 2013
Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settingsA D Revell, D Wang, R Wood, et al.
Nature Medicine|June 17, 1999
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapyT W Chun, D Engel, S B Mizell, et al.
The Journal of Infectious Diseases|March 9, 1999
A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infectionR T Davey, D G Chaitt, J M Albert, et al.
The New England Journal of Medicine|October 16, 2009
Interleukin-2 therapy in patients with HIV infection, , D Abrams, et al.
European Journal of Immunology|July 24, 2001
Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapyJ A Kovacs, S Vogel, J A Metcalf, et al.
Pageof 21

Showing results (191-200 of 209) with videos related to

Sort By:
Pageof 21
The Journal of Infectious Diseases|April 1, 1996
Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trialJ A Kovacs, C Bechtel, R T Davey, et al.
The Journal of Infectious Diseases|September 9, 2000
Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expressionJ A Kovacs, H Imamichi, S Vogel, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1997
Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infectionM A Polis, S C Piscitelli, S Vogel, et al.
The Journal of Infectious Diseases|May 24, 2000
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3M H Losso, W H Belloso, S Emery, et al.
Journal of Virology|July 11, 1996
Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1R Shibata, C Siemon, M W Cho, et al.
The Journal of Antimicrobial Chemotherapy|March 15, 2013
Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settingsA D Revell, D Wang, R Wood, et al.
Nature Medicine|June 17, 1999
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapyT W Chun, D Engel, S B Mizell, et al.
The Journal of Infectious Diseases|March 9, 1999
A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infectionR T Davey, D G Chaitt, J M Albert, et al.
The New England Journal of Medicine|October 16, 2009
Interleukin-2 therapy in patients with HIV infection, , D Abrams, et al.
European Journal of Immunology|July 24, 2001
Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapyJ A Kovacs, S Vogel, J A Metcalf, et al.
Pageof 21